The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
about
Is NF-kappaB a good target for cancer therapy? Hopes and pitfallsTreatment of relapsed and refractory multiple myelomaThe choice of regimens based on bortezomib for patients with newly diagnosed multiple myelomaGood clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Bortezomib in multiple myeloma: systematic review and clinical considerations.How we manage autologous stem cell transplantation for patients with multiple myelomaBetter quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trialEstimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.Bendamustine in patients with relapsed or refractory multiple myeloma.Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients.Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma.Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.Multiple myeloma treatment strategies with novel agents in 2011: a European perspectiveHow to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.Managing multiple myeloma in the elderly: are we making progress?Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.Current therapeutic strategy for multiple myeloma.Association of response endpoints with survival outcomes in multiple myeloma.Controversies in multiple myeloma: to transplant or not?Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques.Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients.Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study.The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.Novel agents in myeloma: an exciting saga.Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.
P2860
Q24570128-B06FA11F-7F36-48AC-84E4-53ADF62EC4ADQ26749180-7C28FA2E-2250-4AA7-9122-2965295ADBB8Q28539605-1192CC4C-9122-4789-A98A-BAF2310B9BAAQ33404749-C4849BA0-6BEB-4495-B022-1637A9AA71A1Q33418705-70EDD2F3-1B37-4906-9936-097A231FC5E5Q33437691-F22C25A0-B61C-483E-BE16-17C7FC790E82Q33982728-4F847C42-33A5-423D-8C34-6732C17979C0Q34019581-78A3D8DC-0B55-4090-9B15-778BB2A052A0Q34166574-9F0F05A5-189B-449D-A36D-D6BA8B5C4EDFQ34291281-DD324122-4ED6-48B9-B10C-42B339B893DAQ34608608-7A772606-FDD9-4B82-96F2-0E8FDFAADCE7Q35125893-0B9B489C-123E-4CF9-AFED-3F05775D354CQ35809982-5CD34D81-B833-4E16-A150-2341A413EBCEQ35868171-7B9290C3-D12C-43C3-B706-60E64F2A3494Q35958553-40CCF830-D166-43B7-B48A-3737DCDFF935Q36115680-A5D7781F-22CA-4E5D-996C-99FF54EF711BQ36301287-1B8E2D17-76EB-459D-936E-D19AFD258BDBQ36525841-C9C7DEF7-353E-4687-902B-9A1DF6AE8B8BQ36562341-79525FC4-92CD-4326-89E2-0056ACAEEAC7Q36750576-D09BD9C1-A5E2-4136-8A1E-D68914B4656FQ37835571-D2A3724B-0C95-4E22-9C31-90228F037C58Q37858327-4B50BC90-B502-46F8-AE0F-26F4F79A1CF9Q37862262-A825FEC6-D4D9-4C97-AA9B-8D7968436BA1Q37888716-42A3F307-977A-490F-B651-246DD8E5C246Q37949201-DA257530-C7BC-4BC1-8296-1CE558738DE2Q38020248-7B79A154-1842-4991-97CE-72687069BAA0Q38072022-685D91A7-9E47-49DE-9C73-F2D2582EEDE6Q38122624-F2F8085E-BEA3-46BE-AD7B-2626511B9A24Q38242006-D8DAB803-498F-4176-BCAF-3D91AC40048AQ38249930-5F2A26B7-4DFE-4FC9-BD67-066F3C0066E7Q38976968-7544CE8B-5D70-4C0B-8817-B624E109D416Q39134450-6243EE3C-C663-42C1-B65E-9BFEAEF39B7BQ41602187-8F60B9D8-75E0-4F9A-A45D-7ECD91D5B4C3Q42119285-7EF949F5-816F-4947-897B-82BB50DA6D29Q42256076-C5035A98-6816-489B-B578-3E57C5E65EA8Q42940532-3E8F0649-9904-4C07-B3BB-252AE8A1DA48Q43761409-0AAC0064-3FBE-44F9-B98D-45A89A70413AQ46233627-90D6816D-C68D-4668-AE91-525671A77680Q47775860-685AA6C0-9F66-48F9-B91B-8ECCDF348AFEQ49641900-B3300118-6212-4D03-90AE-16366D60FF0A
P2860
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The relationship between quali ...... in relapsed multiple myeloma.
@ast
The relationship between quali ...... in relapsed multiple myeloma.
@en
The relationship between quali ...... in relapsed multiple myeloma.
@nl
type
label
The relationship between quali ...... in relapsed multiple myeloma.
@ast
The relationship between quali ...... in relapsed multiple myeloma.
@en
The relationship between quali ...... in relapsed multiple myeloma.
@nl
prefLabel
The relationship between quali ...... in relapsed multiple myeloma.
@ast
The relationship between quali ...... in relapsed multiple myeloma.
@en
The relationship between quali ...... in relapsed multiple myeloma.
@nl
P2093
P50
P1476
The relationship between quali ...... in relapsed multiple myeloma.
@en
P2093
Anthony L Boral
David Irwin
Dixie-Lee Esseltine
Edward A Stadtmauer
Jean-Luc Harousseau
Joan Bladé
Laura Rosiñol
Michael W Schuster
Morton Coleman
P356
10.1111/J.1365-2141.2008.07303.X
P407
P50
P577
2008-07-31T00:00:00Z